Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T and 3T: discrimination of viable from lysed cells.
about
Cytotoxicity, cytocompatibility, cell-labeling efficiency, and in vitro cellular magnetic resonance imaging of gadolinium-catalyzed single-walled carbon nanotubesDetection of intramyocardially injected DiR-labeled mesenchymal stem cells by optical and optoacoustic tomographyClinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors.A biological global positioning system: considerations for tracking stem cell behaviors in the whole body.Cyclodextrin-based bimodal fluorescence/MRI contrast agents: an efficient approach to cellular imaging.MR Imaging of Stem Cell Transplants in Arthritic Joints.Cationic Gd-DTPA liposomes for highly efficient labeling of mesenchymal stem cells and cell tracking with MRI.Monitoring of natural killer cell immunotherapy using noninvasive imaging modalities.The influence of ferucarbotran on the chondrogenesis of human mesenchymal stem cells.MR signal characteristics of viable and apoptotic human mesenchymal stem cells in matrix-associated stem cell implants for treatment of osteoarthritisMR imaging features of gadofluorine-labeled matrix-associated stem cell implants in cartilage defects.In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional labelMagnetic resonance imaging of stem cell apoptosis in arthritic joints with a caspase activatable contrast agent.Imaging Tumor Necrosis with FerumoxytolImaging transplanted stem cells in real time using an MRI dual-contrast method.Intravenous ferumoxytol allows noninvasive MR imaging monitoring of macrophage migration into stem cell transplants.Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects.Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations.Enhancing in vivo survival of adipose-derived stromal cells through Bcl-2 overexpression using a minicircle vectorIron administration before stem cell harvest enables MR imaging tracking after transplantation.Advances in Monitoring Cell-Based Therapies with Magnetic Resonance Imaging: Future PerspectivesThe application of super paramagnetic iron oxide-labeled mesenchymal stem cells in cell-based therapy.Detection of Stem Cell Transplant Rejection with Ferumoxytol MR Imaging: Correlation of MR Imaging Findings with Those at Intravital Microscopy.In vivo quantitative assessment of cell viability of gadolinium or iron-labeled cells using MRI and bioluminescence imaging.Somatic differentiation and MR imaging of magnetically labeled human embryonic stem cells.In vivo MRI discrimination between live and lysed iron-labelled cells using balanced steady state free precession.Mesenchymal stem cell labeling and in vitro MR characterization at 1.5 T of new SPIO contrast agent: Molday ION Rhodamine-B™.Fluorescence molecular tomography of DiR-labeled mesenchymal stem cell implants for osteochondral defect repair in rabbit knees.Magnetic resonance imaging and tracking of stem cells.The Protein Corona around Nanoparticles Facilitates Stem Cell Labeling for Clinical MR Imaging.Ten Things You Might Not Know about Iron Oxide Nanoparticles.In vivo MRI mapping of iron oxide-labeled stem cells transplanted in the heart.Engineering stem cells for treatment of osteochondral defects.Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer
P2860
Q28389202-DA566CDA-9EA6-4A45-9266-4C6EDEB9AE2AQ30355871-ADEA7F7E-EF46-4A38-B9BE-2B4756EB2A35Q30930526-522A6FA3-EAE8-473E-B7A6-5BD6C98DD754Q33541898-9389FEE2-EF4D-4BB0-B2AD-28895BF69E55Q33617992-5BD59787-0877-46E4-AC2A-8A1094D53075Q33949771-99EABADF-6CB4-44CF-A182-29FF36627B3BQ34022435-A9AE336B-4DF7-428F-8E15-F1238EF919D5Q34049387-FC6D2380-0E66-45AD-876B-F5FD44F98C2BQ34105714-D5FC0073-B762-4246-84AB-343827972867Q34146129-FB9392BB-C738-4E92-B5D9-48801B4BE359Q34515707-D5F0A158-C391-426D-9372-4994035518CAQ34698260-2D39CFA6-6E41-4CDB-BFDA-89BCEDA2DA42Q35637325-B7413625-C0D9-464A-9AEF-57BDC9E4B667Q35841636-BE5FCB64-F5EC-44BF-B00E-B81D7B87CBA3Q36017919-4F28BEC6-223E-4FF8-885E-C008BA7E210DQ36186646-D08783A7-7B05-48F9-9F52-349C6809D455Q36897566-EE835885-0AB4-4CBE-9EB5-694F8C05DC41Q37055293-7A7A0A7B-68B1-41AC-B70D-F31CA2395EBFQ37124564-1E700A5F-0B9F-4578-B460-40DECC79F31FQ37193042-68793068-8AAA-406E-BEC2-85C1ED80FF8EQ37631684-B0340E49-E62C-4C4A-8D6F-A81A440254DBQ38069962-77107ACA-D11A-40D7-994C-6AF8DB9EFCEAQ38995648-8375E568-FCC5-45DC-9178-76BCC9CF8798Q39217789-7370F231-50E8-4028-B4D1-31AB7D1ED798Q39302728-690A14D2-04A0-4AFA-B58D-A35BA3B91582Q39357801-0196FC0B-DDB6-4647-ACF2-6E72D41DEE57Q39982412-C732EA48-FD42-4B17-BD64-E5BF14A7A85DQ40688805-21679E74-81CB-4A51-BCC0-345C20F84301Q42757612-F8A8F323-4284-4A46-8D1E-AE91142FD8ADQ47391647-7F092A5C-C406-4C63-9E4A-A0DF142B1285Q48146534-D62A045D-B24E-497F-B823-FD61E5C83718Q50625476-EF014DF9-86C9-47D8-BEE0-EC6898B1C2AAQ50670026-39D1E01A-FB5A-441E-B034-CE6DE8DC120AQ58562134-90285B37-EB3B-47EC-B285-9169B93D6EDB
P2860
Relaxation effects of ferucarbotran-labeled mesenchymal stem cells at 1.5T and 3T: discrimination of viable from lysed cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Relaxation effects of ferucarb ...... on of viable from lysed cells.
@en
Relaxation effects of ferucarb ...... on of viable from lysed cells.
@nl
type
label
Relaxation effects of ferucarb ...... on of viable from lysed cells.
@en
Relaxation effects of ferucarb ...... on of viable from lysed cells.
@nl
prefLabel
Relaxation effects of ferucarb ...... on of viable from lysed cells.
@en
Relaxation effects of ferucarb ...... on of viable from lysed cells.
@nl
P2093
P2860
P50
P356
P1476
Relaxation effects of ferucarb ...... ion of viable from lysed cells
@en
P2093
Barbara Sennino
Daniel Golovko
Donald M McDonald
Farbod Malek
Michael F Wendland
Tobias D Henning
P2860
P304
P356
10.1002/MRM.22011
P577
2009-08-01T00:00:00Z